Global Bioenergies has received letters of intent for its plant project corresponding to forecasted annual sales of over €70 million
This plant, mainly dedicated to cosmetics, will be commissioned during 2027 and will market Isonaturane™ 12 and 16, the first natural-origin equivalents to petroleum-based isododecane and isohexadecane.
- This plant, mainly dedicated to cosmetics, will be commissioned during 2027 and will market Isonaturane™ 12 and 16, the first natural-origin equivalents to petroleum-based isododecane and isohexadecane.
- Concurrently with commercial development and under the supervision of Roland Desvignes, Industrial Director of Global Bioenergies, the engineering teams have finalised the first plant layouts.
- Based on these layouts, the total construction cost of the plant (including hazards) has been estimated at nearly €80 million.
- This will be followed by the construction phase of the plant itself, which will involve the main CAPEX outflows, and will be completed in 2027.